Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.370
-0.010 (-0.42%)
Aug 22, 2025, 4:00 PM - Market closed
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia.
The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Maria Maccecchini |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | 484 875 3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President and Executive Director |
| Andrew Walsh | Principal Financial Officer |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research and Development |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Melissa Gaines | Senior Vice President of Clinical Operations |
| Blake Jensen M.B.A. | Head of Quality |
| Hilda Maibach | Senior Vice President of Statistics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 15, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | ARS | Filing |
| May 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |